Can we target AML with CAR T-cells?
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz
Targeted therapies for CLL: new data and unanswered questions